AstraZeneca (NYSE: AZN) has announced that FASLODEX 500mg packs are now available for physicians to order. FASLODEX 500 mg is approved for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy...
More...